Please login to the form below

Not currently logged in
Email:
Password:

Roche and Evotec form biomarker alliance

Roche and Evotec are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development

Roche and Evotec, a drug discovery company specialising in development partnerships, are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec will employ its PhosphoScout platform to discover protein-phosphorylation's that predict favourable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials, as well as assessing the development of companion diagnostics for patient stratification.

Mike Burgess, global head of oncology at Roche Pharma Research and Exploratory Development, said: "We are very pleased to collaborate with Evotec and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers. They are core to the development of targeted therapeutics for cancer therapy."

Under the initial three-year term Roche and Evotec will conduct multiple biomarker programmes for therapeutic antibodies or small molecule inhibitors.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics